The current study,The Phase 2b study titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease” (“CUPID Phase 2b Trial”) is a multinational, multicenter, double-blind, placebo-controlled, randomized study currently recruiting subjects in the United States and in Europe. Results are anticipated in the first half of 2015. Please visit the ClincalTrials.gov website for more information, or call Celladon Corporation 1-858-366-4288.
The phase 2 CUPID Trial successfully met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR® versus placebo. Additionally, 12 months after receiving a single infusion of MYDICAR®, patients treated with the highest dose versus placebo had an 88 percent reduction of major cardiovascular events* such as death, need for left ventricular assist device (LVAD) or cardiac transplant, and number of heart failure-related hospitalizations.
Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR®, a potential breakthrough for the treatment of severe heart failure. MYDICAR is designed to restore a critical enzyme necessary for the heart to pump more efficiently. Read More
We are a clinical-stage biotechnology company applying our leadership position in the field of SERCA enzymes to develop novel therapies that may transform the lives of patients in a number of diseases with tremendous unmet medical needs. MYDICAR, our most advanced product candidate, currently in a Phase 2b trial, targets SERCA2a, which is an enzyme that becomes deficient in patients with advanced heart failure. We believe that our approach to modulating SERCA2a addresses this key enzyme deficiency through gene therapy and has the potential to provide transformative disease modifying effects with life-long clinical benefits based on a single therapeutic administration. Read More